Trending Now
Stocks for the Pandemic Long Haul (FLGT, ALST, HOLX)
Scientists are beginning to arrive at the notion that the fight with Covid-19 is not a short raging battle that will be...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Obseva SA (NASDAQ: OBSV) Receives Another Positive Review From the CHMP
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has repeated its positive review of Obseva SA's (NASDAQ: OBSV) Linzagolix....
MAKE IT MODERN
LATEST REVIEWS
Xeris Pharmaceuticals Inc (NASDAQ:XERS) Receives Fast Track Designation For XP-0863 From...
Xeris Pharmaceuticals Inc (NASDAQ:XERS) recently announced that XP-0863, its innovative developmental treatment for acute repetitive seizures, received fast track designation from the Food and...
MAKE IT MODERN
PERFORMANCE TRAINING
Aileron Therapeutics Inc. (NASDAQ:ALRN) Reports Positive Preliminary Phase 1b/2 ALRN-6924 Clinical Study Results For...
Aileron Therapeutics Inc. (NASDAQ:ALRN) has announced positive preliminary results of the company’s dose optimization portion of Phase 1b open-label trial of the continuing Phase1b/2...
BELLUS Health Inc. (NASDAQ:BLU) Reports Q3 2020 Financial Results And Progress of BLU-5937 Development
BELLUS Health Inc. (NASDAQ:BLU) has reported its operating and financial results for the three months ended September 30, 2020.
ADC Therapeutics SA Soars on Positive Preliminary Results from ZYNLONTA® Clinical Trial
ADC Therapeutics SA (NYSE: ADCT), a frontrunner in the field of antibody drug conjugates (ADCs), has recently captivated the attention of...
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Reports Preliminary Q3 2021 Results And Data Analyse From...
Sarepta Therapeutics Inc. (NASDAQ: SRPT) has announced its preliminary Q3 2021 financial results. The company expects net product revenues of $166.9 million relative to...
Geron Corporation (NASDAQ:GERN) Remains an Interesting Lotto Ticket
Geron Corporation
(NASDAQ:GERN) represents the ultimate Hail Mary pass in many ways at this
point, but one well worth a deeper look. If you...
MAKE IT MODERN
